IQVIA Holdings Inc (IQV)
NYSE:IQV
Top Page
IQVIA Holdings
(NYSE:IQV)
Select Model
Select Model
Rating:59Neutral
Price Target:
$174.00
▲(4.76% Upside)
Action:ReiteratedDate:02/07/26
The score is driven primarily by decent underlying fundamentals but constrained by high leverage and recent margin/cash-flow pressure. Technicals are notably weak (below major moving averages with bearish momentum), while valuation is only moderate. The latest earnings call was constructive with solid FY2026 guidance and strong backlog, partially offset by margin pressure and rising interest expense.
Positive Factors
Steady revenue growth & diversified services
IQVIA’s multi-year revenue expansion reflects durable demand across CRO, technology/analytics, and commercial outsourcing. Sustained top-line growth from diversified service lines reduces single-market risk and supports long-term scale benefits, pricing power, and cross-sell opportunities.
Negative Factors
High leverage and rising interest costs
Elevated leverage and increased debt reduce financial flexibility and heighten sensitivity to rates or earnings shocks. Higher net interest expense will persistently pressure free cash flow available for buybacks, debt paydown, or reinvestment absent multi-year deleveraging or materially stronger operating cash conversion.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue growth & diversified services
IQVIA’s multi-year revenue expansion reflects durable demand across CRO, technology/analytics, and commercial outsourcing. Sustained top-line growth from diversified service lines reduces single-market risk and supports long-term scale benefits, pricing power, and cross-sell opportunities.
Read all positive factors
IQVIA Holdings (IQV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$28.33B
Dividend YieldN/A
Average Volume (3M)2.52M
Price to Earnings (P/E)28.5
Beta (1Y)0.89
Revenue Growth3.85%
EPS Growth-4.74%
CountryUS
Employees89,000
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)3.42
Shares Outstanding169,700,000
10 Day Avg. Volume1,624,784
30 Day Avg. Volume2,518,876
Financial Highlights & Ratios
PEG Ratio6.34
Price to Book (P/B)5.96
Price to Sales (P/S)2.38
P/FCF Ratio18.89
Enterprise Value/Market Cap1.49
Enterprise Value/Revenue2.59
Enterprise Value/Gross Profit9.87
Enterprise Value/Ebitda12.21
Forecast
1Y Price Target
$227.62Price Target Upside37.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)12.69
Revenue Forecast (FY)$17.24B
IQVIA Holdings Business Overview & Revenue Model
Company Description
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics S...
How the Company Makes Money
IQVIA makes money by selling contracted services and technology solutions primarily to life sciences customers, with revenue largely generated from service fees under multi-month or multi-year agreements. Its key revenue streams include: (1) Resea...
IQVIA Holdings Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyIQVIA Holdings Earnings Call Summary
Earnings Call Date:Feb 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 23, 2026
Earnings Call Sentiment Positive
Overall the call presented solid demand recovery (strong bookings, record backlog), healthy revenue and EPS growth, robust cash generation, and constructive FY2026 guidance alongside strategic AI and M&A investments. Offsetting risks discussed included slightly elevated cancellations, margin pressure driven by pass‑throughs and product mix, and elevated leverage with higher interest expense. On balance, management portrayed confidence in secular growth drivers and positioning to monetize AI and integrated offerings.Positive Updates
Full‑Year Revenue and EPS Growth
Full‑year 2025 revenue of $16.31B, up 5.9% reported (4.8% constant currency); full‑year adjusted diluted EPS $11.92, up 7.1% year‑over‑year.
Negative Updates
Macroeconomic Headwinds and Funding Pressure
Management cited heightened macroeconomic and policy uncertainty and elevated interest rates that slowed customer decision‑making and tempered biotech funding earlier in the year, which weighed on R&D bookings.
Read all updates
Q4-2025 Updates
Positive
Negative
Full‑Year Revenue and EPS Growth
Full‑year 2025 revenue of $16.31B, up 5.9% reported (4.8% constant currency); full‑year adjusted diluted EPS $11.92, up 7.1% year‑over‑year.
Read all positive updates
Company Guidance
IQVIA guided full‑year 2026 revenue of $17.159–$17.359 billion (including ~150 bps from M&A and ~100 bps FX tailwind), adjusted EBITDA of $3.975–$4.25 billion and adjusted diluted EPS of $12.55–$12.85; they expect operating D&A of about $610 million, net interest expense of ~ $760 million (≈$80 million higher versus 2025), an effective tax rate just over 17%, and average diluted shares just over 171 million (assuming FX rates as of Feb 4). On a recast basis by new segments, 2026 Commercial Solutions revenue is expected at $7.2–$7.3 billion (≈7–9% growth) and R&D Solutions at $9.9–$10.0 billion (≈4% growth at midpoint). For Q1 management guided adjusted EBITDA of $920–$940 million and adjusted diluted EPS of $2.77–$2.80.IQVIA Holdings Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
56
Neutral
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 16.31B | 15.40B | 14.98B | 14.41B | 13.87B |
| Gross Profit | 4.29B | 5.38B | 5.24B | 5.03B | 4.64B |
| EBITDA | 3.46B | 3.45B | 3.26B | 2.91B | 2.77B |
| Net Income | 1.36B | 1.37B | 1.36B | 1.09B | 966.00M |
Balance Sheet | |||||
| Total Assets | 29.94B | 26.90B | 26.68B | 25.34B | 24.69B |
| Cash, Cash Equivalents and Short-Term Investments | 2.14B | 1.84B | 1.50B | 1.31B | 1.48B |
| Total Debt | 16.17B | 14.16B | 13.90B | 13.01B | 12.44B |
| Total Liabilities | 23.31B | 20.83B | 20.57B | 19.57B | 18.65B |
| Stockholders Equity | 6.50B | 6.07B | 6.11B | 5.76B | 6.04B |
Cash Flow | |||||
| Free Cash Flow | 2.05B | 2.11B | 1.50B | 1.59B | 2.30B |
| Operating Cash Flow | 2.65B | 2.72B | 2.15B | 2.26B | 2.94B |
| Investing Cash Flow | -2.31B | -1.44B | -1.60B | -2.01B | -2.10B |
| Financing Cash Flow | -150.00M | -878.00M | -382.00M | -329.00M | -1.24B |
IQVIA Holdings Technical Analysis
Negative
166.09
Price Trends
192.70
Negative
208.21
Negative
195.69
Negative
Market Momentum
-6.07
Negative
39.35
Neutral
33.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IQV, the sentiment is Negative. The current price of 166.09 is below the 20-day moving average (MA) of 170.25, below the 50-day MA of 192.70, and below the 200-day MA of 195.69, indicating a bearish trend. The MACD of -6.07 indicates Negative momentum. The RSI at 39.35 is Neutral, neither overbought nor oversold. The STOCH value of 33.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IQV.
IQVIA Holdings Risk Analysis
IQVIA Holdings disclosed 51 risk factors in its most recent earnings report. IQVIA Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IQVIA Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $13.08B | 35.91 | 118.82% | ― | 13.88% | 23.92% | |
70 Outperform | $7.66B | 1,437.41 | 6.32% | ― | -2.46% | -17.89% | |
70 Neutral | $21.49B | 19.42 | 13.88% | 1.80% | 13.74% | 14.87% | |
67 Neutral | $134.36B | 44.80 | 6.99% | 0.53% | 2.90% | -4.81% | |
63 Neutral | $182.14B | 32.34 | 13.15% | 0.30% | 3.91% | 7.09% | |
59 Neutral | $28.33B | 28.49 | 22.28% | ― | 3.85% | -4.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IQV
IQVIA Holdings
166.09
-13.93
-7.74%
DHR
Danaher
190.10
-19.00
-9.09%
ICLR
Icon
101.28
-77.50
-43.35%
DGX
Quest Diagnostics
196.08
32.50
19.87%
TMO
Thermo Fisher
490.29
-21.50
-4.20%
MEDP
Medpace Holdings
460.74
143.09
45.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.